Butenafine and superficial mycoses: current status

Bibliography

• Pierard GE, Arrese JE, Pierard-FC: Treatment and prophylaxis of tinea infections. Drugs 1996;52:209-24
   PubMed Web of Science ®Google Scholar
• Medoff G, Kobayashi GA. The polkyenes. In: Speller DCE, editor, Antifungal chemotherapy. Chichester, England: John Wiley; 1980. p. 3-33
   Google Scholar
• Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs 1998;55:645-74
   PubMed Web of Science ®Google Scholar
• Mcneely W, Spencer CM. Butenafine. Drugs 1998;55:405-12
   PubMed Web of Science ®Google Scholar
• Elewski BE: Mechanism of action of systemic antifungal agents. J Am Acad Dermatol 1997;28:S28-34
   Google Scholar
• Syed TA, Maibach HI. Butenafine hydrochloride: for the treatment of interdigital tinea pdis. Exp Opin Pharmacother 2000;1(3):467-73
   PubMedGoogle Scholar
• Maeda T, Takase M, Ishibashi A, et al. Synthesis and antifungal activity of butenafine hydrochloride(KP-363), a new benzylamine antifungal agent. Yakugaku Zasshi 1991;111:126-37
   PubMed Web of Science ®Google Scholar
• Arika T, Yokoo M, Hase T, et al. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs. Antimicrob Agents Chemother 1990;34:2250-3
   PubMed Web of Science ®Google Scholar
• Arika T, Yokoo M, Maeda T, et al. Effect of butenafine hydrochloride, a new benzylamine derivative, on experimental tinea pedis in guinea pigs. Antimicrob Agents Chemother 1990;34:2254-5
   PubMed Web of Science ®Google Scholar
• Hiratani T, Asagi Y, Yamaguchi H. Studies on antifungal mechanism of butenafine hydrochloride. I. Inhibition of squalene epoxidation and damaging of cell membranes in Sporothrix schenckii cells. Jpn J Med Mycol 1991;32:139-49
   Google Scholar
• Hiratani T, Asagi Y, Yamaguchi H. Studies on antifungal mechanism of butenafine hydrochloride. II. Comparison in the response to drug treatment between a wild-type strainand tolcicate-resistant mutant strains of Sporothrix schensckii. Jpn J Med Mycol 1991;32:151-7
   Google Scholar
• Iwatani W, Arika T, Yamaguchi H. Two Mechanisms of Butenafine Action in Candida albicans. Antimicrob Agents Chemother 1993;37:785-8
   PubMed Web of Science ®Google Scholar
• Nahm WK, Orengo I, Rosen T. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. J Am Acad Dermatol. 1999;41:203-6
   PubMed Web of Science ®Google Scholar
• Arika T, Hase T, Yokoo M. Anti-Trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs. Antimicrob Agents Chemother 1993;37:363-5
   PubMed Web of Science ®Google Scholar
• Lesher JL, Babel DE, Stewart DM, et al. Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehiclecontrolled, double-blind trial. J Am Acad Dermatol 1997;36:S20-4
   Google Scholar
• Nimura K, Niwano Y, Ishiduka S, et al. Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. Int J Antimicrob Agents 2001;18(2):173-8
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Gallet X, Flore C, et al. Experimental and conformational analyses of interactions between butenafine and lipids. Antimicrob Agents Chemother 2001;45:3347-54
   PubMed Web of Science ®Google Scholar
• Arika T, Yokoo M, Yamaguchi H. Topical treatment with butenafine significantly lowers relapse rate in an interdigital tinea pedis model in guinea pigs. Antimicrob Agents Chemother 1992;36(11):2523-5
   PubMed Web of Science ®Google Scholar
• Fukushiro R, Urabe H, Kagwa S. Butenafine hydrochloride, a new antifungal agent: clinical and experimental study. In: Yamaguchi H. Kobayashi GS, Takahashi H, editors, Recent progress in antifungal therapy. New York: Marcel Dekkar; 1992. p. 142-57
   Google Scholar
• Savin R, De Villez RL, Elewski B, et al. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. J Am Acad Dermatol 1997;36:S15-9
   Google Scholar
• Tschen E, Elewski B, Goruslowski DC, et al. Treatment of interdigital tinea pedis with a 4-week once daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997;36:S9-14
   Web of Science ®Google Scholar
• Reyes BA, Beutner KR, Cullen SI, et al. Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Int J Dermatol 1998;37:433-53
   PubMed Web of Science ®Google Scholar
• Tanuma H, Doi M, Ohta Y, et al. Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin). Mycoses 2001;44:287-99
   PubMed Web of Science ®Google Scholar
• Syed TA, Ahmadpour OA, Ahmad SA, et al. Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo controlled double-blind study. J dermatol 1998;10:648-52
   Google Scholar
• Syed TA, Qureshi ZA, Ali SM, et al. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Tro Med Int Health 1999;4:284-7
   PubMed Web of Science ®Google Scholar
• Greer DL, Weiss J, Rodriguez DA, et al. A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent. J Am Acad Dermatol 1997;37:231-5
   PubMed Web of Science ®Google Scholar
• Singal A, Pandhi D, Agrawal S, et al. Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial. J Dermatolog Treat 2005;16:331-5
   PubMed Web of Science ®Google Scholar
• Ramam M, Prasad HR, Manchanda Y, et al. Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis: Indian J Dermatol Venereol Leprol 2003;69(2):154-8
   PubMedGoogle Scholar
• Butenafine HCl cream, 1%, Mentax® package insert. Bertek Pharmaceuticals, Inc., NC, USA; 2001
   Google Scholar
• Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol 2004;5(6):417-22
   PubMed Web of Science ®Google Scholar
• Gupta AK, Yokou M, Arika T, et al. Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream against Malassezia furfur species and seborrheic dermatitis. J Dermatol Treat 2000;11:79-83
   Web of Science ®Google Scholar
• Gupta AK. Butenafine: an update of its use in superficial mycoses. Skin Ther Lett 2002;7(7):1-2, 5
   Google Scholar
• Itoh M. Skin safety of KP-363, a new antifungal agent, in healthy volunteers-comparative study with other antifungals. Skin Res 1988;30:507-13
   Google Scholar